# Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

> **NCT00045968** · PHASE3 · UNKNOWN · sponsor: **Northwest Biotherapeutics** · enrollment: 348 (estimated)

## Conditions studied

- Glioblastoma Multiforme
- Glioblastoma
- GBM
- Grade IV Astrocytoma
- Glioma
- Brain Cancer
- Brain Tumor

## Interventions

- **DRUG:** Dendritic cell immunotherapy

## Key facts

- **NCT ID:** NCT00045968
- **Lead sponsor:** Northwest Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-12
- **Primary completion:** 2022-11
- **Final completion:** —
- **Target enrollment:** 348 (ESTIMATED)
- **Last updated:** 2022-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00045968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00045968, "Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00045968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*